U.S. Sluggish In Commitment To Marine Biotechnology

While Japan is bearish on the potentially lucrative field, American government and industry fail to show enthusiasm or backing WASHINGTON -- To promoters of U.S. competitiveness, Japan's Ministry of International Trade and Industry sometimes seems invincible. MITI has an enviable reputation for helping industry develop new products - often based on United States discoveries - that eventually dominate global markets. So MITI's decision to spend almost $200 million in the next decade on marine b

Written byElizabeth Pennisi
| 9 min read

Register for free to listen to this article
Listen with Speechify
0:00
9:00
Share


While Japan is bearish on the potentially lucrative field, American government and industry fail to show enthusiasm or backing
WASHINGTON -- To promoters of U.S. competitiveness, Japan's Ministry of International Trade and Industry sometimes seems invincible. MITI has an enviable reputation for helping industry develop new products - often based on United States discoveries - that eventually dominate global markets. So MITI's decision to spend almost $200 million in the next decade on marine biotechnology (The Scientist, March 19, 1990, page 1) has raised eyebrows at the U.S. laboratories where this science was conceived.

But some U.S. researchers are confident that they can hold their own against this Asian Goliath. They are "the American answer to MITI," says Ronald Cape, board chairman of Cetus Corp., of Emeryville, Calif. But they say they need the backing of the U.S. government and industry.

Rita Colwell is one such scientist. In 1985 the ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies